Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NYSE:ANVS NASDAQ:CNTX NASDAQ:MGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.54-1.3%$1.85$0.40▼$2.66$209.92M0.441.06 million shs858,228 shsANVSAnnovis Bio$1.89-5.3%$2.02$1.54▼$5.50$68.95M1.271.25 million shs1.40 million shsCNTXContext Therapeutics$1.75-13.8%$2.45$0.55▼$3.62$186.51M1.61647,568 shs821,585 shsMGNXMacroGenics$3.91-8.0%$3.58$1.18▼$4.64$248.53M1.181.47 million shs559,965 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-1.28%-18.95%-26.32%-30.32%+188.34%ANVSAnnovis Bio-4.56%-2.08%-21.29%-24.30%-41.64%CNTXContext Therapeutics-13.79%-38.60%-27.39%-43.91%+204.19%MGNXMacroGenics-8.00%-6.01%+29.90%+75.34%+160.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.54-1.3%$1.85$0.40▼$2.66$209.92M0.441.06 million shs858,228 shsANVSAnnovis Bio$1.89-5.3%$2.02$1.54▼$5.50$68.95M1.271.25 million shs1.40 million shsCNTXContext Therapeutics$1.75-13.8%$2.45$0.55▼$3.62$186.51M1.61647,568 shs821,585 shsMGNXMacroGenics$3.91-8.0%$3.58$1.18▼$4.64$248.53M1.181.47 million shs559,965 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-1.28%-18.95%-26.32%-30.32%+188.34%ANVSAnnovis Bio-4.56%-2.08%-21.29%-24.30%-41.64%CNTXContext Therapeutics-13.79%-38.60%-27.39%-43.91%+204.19%MGNXMacroGenics-8.00%-6.01%+29.90%+75.34%+160.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60198.70% UpsideANVSAnnovis Bio 2.25Hold$13.50616.18% UpsideCNTXContext Therapeutics 2.88Moderate Buy$6.60277.14% UpsideMGNXMacroGenics 2.29Hold$5.5040.66% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ALXO, MGNX, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026MGNXMacroGenics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026MGNXMacroGenics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.004/14/2026ANVSAnnovis Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.004/10/2026MGNXMacroGenics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.00 ➝ $9.003/24/2026CNTXContext Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/24/2026CNTXContext Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/24/2026CNTXContext Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $7.003/19/2026ALXOALX Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$5.003/10/2026ALXOALX Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/AANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AMGNXMacroGenics$157.08M1.58N/AN/A$0.88 per share4.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/18/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)MGNXMacroGenics-$74.62M-$1.10N/AN/AN/A-44.79%-147.80%-28.40%8/13/2026 (Estimated)Latest ANVS, ALXO, MGNX, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/13/2026Q1 2026MGNXMacroGenics-$0.57-$0.58-$0.01-$0.58$15.24 million$20.78 million5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/A3/9/2026Q4 2025ALXOALX OncologyN/A-$0.42N/A-$0.42N/AN/A3/9/2026Q4 2025MGNXMacroGenics-$0.42-$0.2241+$0.1959-$0.22$27.81 million$41.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.027.217.21ANVSAnnovis BioN/A1.271.27CNTXContext TherapeuticsN/A8.968.96MGNXMacroGenicsN/A1.901.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%ANVSAnnovis Bio15.83%CNTXContext Therapeutics14.03%MGNXMacroGenics96.89%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%ANVSAnnovis Bio20.80%CNTXContext Therapeutics4.80%MGNXMacroGenics13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.31 millionOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableMGNXMacroGenics43063.56 million54.92 millionOptionableANVS, ALXO, MGNX, and CNTX HeadlinesRecent News About These CompaniesMacroGenics, Inc. (NASDAQ:MGNX) Sees Large Increase in Short InterestJune 5 at 4:42 AM | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Shares Pass Above 50-Day Moving Average - What's Next?June 4 at 3:23 AM | americanbankingnews.comMacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline UpdatesMay 27, 2026 | marketbeat.comHow The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution RisksMay 22, 2026 | finance.yahoo.comMacroGenics Shareholders Back Board, Auditors and Equity PlanMay 20, 2026 | tipranks.comMacrogenics Inc.May 16, 2026 | marketwatch.comMacroGenics, Inc. (NASDAQ:MGNX) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 15, 2026 | finance.yahoo.comMacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology ForumMay 14, 2026 | globenewswire.comMacroGenics: Q1 Earnings SnapshotMay 13, 2026 | chron.comGMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)May 13, 2026 | finance.yahoo.comMacroGenics (MGNX) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2026 | zacks.comMacroGenics Reports First Quarter 2026 Financial Results and Highlights Business TransformationMay 13, 2026 | globenewswire.comMacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 MillionMay 11, 2026 | quiverquant.comQMacroGenics to Sell GMP Manufacturing Operations to Bora PharmaceuticalsMay 11, 2026 | globenewswire.comHC Wainwright Forecasts Increased Earnings for MacroGenicsMay 11, 2026 | marketbeat.comMacroGenics Expands ZYNYZ Royalty Agreement for Added FundingMay 6, 2026 | theglobeandmail.comWill MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should KnowMay 5, 2026 | zacks.comMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase AgreementMay 4, 2026 | globenewswire.comMacroGenics (MGNX) price target increased by 50.00% to 6.12April 29, 2026 | msn.comB. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector ActivityApril 17, 2026 | insidermonkey.comB Riley Securities upgrades MacroGenics (MGNX)April 11, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANVS, ALXO, MGNX, and CNTX Company DescriptionsALX Oncology NASDAQ:ALXO$1.54 -0.02 (-1.28%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.32%) As of 06/5/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Annovis Bio NYSE:ANVS$1.88 -0.11 (-5.28%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 06/5/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Context Therapeutics NASDAQ:CNTX$1.75 -0.28 (-13.79%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.85 +0.10 (+5.71%) As of 06/5/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.MacroGenics NASDAQ:MGNX$3.91 -0.34 (-8.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.91 +0.00 (+0.08%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
